ICON PLC (ICLR) FinancialsICLRICON PLC

ICON PLC (ICLR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical Research, accounting for 92.3% of total sales, equivalent to $277.16M. Another important revenue stream is Central Laboratories. Understanding this composition is critical for investors evaluating how ICLR navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, ICON PLC maintains a gross margin of 18.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.41%, while the net margin is 3.52%. These profitability ratios, combined with a Return on Equity (ROE) of 0.45%, provide a clear picture of how effectively ICLR converts its operational activities into shareholder value.

In the context of the broader market, ICLR competes directly with industry leaders such as CRL and ULS. With a market capitalization of $12.59B, it holds a significant position in the sector. When comparing efficiency, ICLR's gross margin of 18.83% stands against CRL's 36.29% and ULS's 51.10%. Such benchmarking helps identify whether ICON PLC is trading at a premium or discount relative to its financial performance.

ICON PLC's revenue shows a slight upward trend, with Q2 2026 revenue at $2.06 billion, exceeding expectations. However, net income has fluctuated significantly, dropping to $7.25 million in Q2 2026 after a loss in Q4 2025.